Results 41 to 50 of about 389,573 (268)

Chikungunya vaccines in development [PDF]

Human Vaccines & Immunotherapeutics, 2015
Chikungunya virus has become a global health threat, spreading to the industrial world of Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late 1960s much effort has been put into the development of a vaccine, and several heterogeneous strategies have already been explored.
Schwameis, Michael, Buchtele, Nina, Wadowski, Patricia Pia, Schoergenhofer, Christian, Jilma, Bernd   +4 more
openaire   +2 more sources

Low Incidence of Relapses After Vaccination in Anti‐Aquaporin‐4 Antibody‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%–10.6 ...
Sean J. Pittock, Jin Nakahara, Becky Parks, Kerstin Allen, Sami Fam   +4 more
wiley   +1 more source

Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines

npj Vaccines
Seasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually.
Teresa Hauguel, Amy Sharma, Emily Mastrocola, Susan Lowry, Mohan S. Maddur, Cheng Hui Hu, Swati Rajput, Allison Vitsky, Shambhunath Choudhary, Balasubramanian Manickam, Ivna De Souza, Yana Chervona, Raquel Munoz Moreno, Charisse Abdon, Larissa Falcao, Kristin Tompkins, Deanne Illenberger, Rachel Smith, Fanyu Meng, Shuai Shi, Kari Sweeney Efferen, Victoria Markiewicz, Cinthia Umemoto, Jianfang Hu, Wei Chen, Ingrid Scully, Cynthia M. Rohde, Annaliesa S. Anderson, Pirada Suphaphiphat Allen   +28 more
doaj   +1 more source

Modeling excess zeroes in an integrated analysis of vaccine safety

Human Vaccines & Immunotherapeutics, 2018
In prophylactic vaccine studies in healthy populations, many subjects do not experience a single adverse event (AE). Thus, the number of AEs observed in such clinical trials may be difficult to model because of an excess of zeroes relative to the ...
Roger Maansson, David Radley, Qin Jiang, Johannes Beeslaar, Scott Patterson, Judith Absalon, John Perez   +6 more
doaj   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

Development of a schistosomiasis vaccine [PDF]

Expert Review of Vaccines, 2016
Schistosomiasis is a neglected tropical disease (NTD) of public health importance. Despite decades of implementation of mass praziquantel therapy programs and other control measures, schistosomiasis has not been contained and continues to spread to new geographic areas.
Adebayo J, Molehin, Juan U, Rojo, Sabrina Z, Siddiqui, Sean A, Gray, Darrick, Carter, Afzal A, Siddiqui   +5 more
openaire   +2 more sources

COVID‐19 Vaccination Is Not Associated With the Development of Idiopathic Inflammatory Myositis in US Veterans

Arthritis Care &Research, EarlyView.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández, Naomi Schlesinger, Jorge Rojas, Jessica A. Walsh, Tawnie J. Braaten, Gary A. Kunkel, Makoto Jones, Brian C Sauer, Julio Facelli, Grant W. Cannon, Dorota Lebiedz‐Odrobina   +10 more
wiley   +1 more source

Developing an HIV vaccine [PDF]

Science, 2017
What are the paths and obstacles to a practical vaccine?
Barton F, Haynes, Dennis R, Burton
openaire   +2 more sources

Developing and Evaluating a Laboratory‐Based Frailty Index for the Prediction of Long‐Term Health Outcomes in Systemic Lupus Erythematosus

Arthritis Care &Research, EarlyView.
Objective We aimed to construct and evaluate the first laboratory‐based frailty index (FI‐Lab) for predicting adverse outcomes in systemic lupus erythematosus (SLE) and to compare its predictive ability to that of an existing clinical FI. Methods We used data from a single‐center prospective cohort of adult patients with SLE whose baseline visit ...
Grace Burns, Samuel D. Searle, Alexandra Legge   +2 more
wiley   +1 more source

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

npj Vaccines
As SARS-CoV-2 evolves, increasing in potential for greater transmissibility and immune escape, updated vaccines are needed to boost adaptive immunity to protect against COVID-19 caused by circulating strains.
Kayvon Modjarrad, Ye Che, Wei Chen, Huixian Wu, Carla I. Cadima, Alexander Muik, Mohan S. Maddur, Kristin R. Tompkins, Lyndsey T. Martinez, Hui Cai, Minah Ramos, Sonia Mensah, Brittney Cumbia, Larissa Falcao, Andrew P. McKeen, Jeanne S. Chang, Kimberly F. Fennell, Kevin W. Huynh, Thomas J. McLellan, Parag V. Sahasrabudhe, Wei Chen, Michael Cerswell, Miguel A. Garcia, Shilong Li, Rahul Sharma, Weiqiang Li, Kristianne P. Dizon, Stacy Duarte, Frank Gillett, Rachel Smith, Deanne M. Illenberger, Kari Sweeney Efferen, Annette B. Vogel, Annaliesa S. Anderson, Uğur Şahin, Kena A. Swanson   +35 more
doaj   +1 more source